Novel Research In The Cell And Gene Sector

The novel cell and gene therapies in the development pipeline today are the result of years of pioneering research by world-class, U.S.-based academic universities and biopharmaceutical research companies. Given the number of clinical trials in various stages, the U.S. Food and Drug Administration (FDA) expects that it will receive more than 200 investigational new drug applications a year through 2025. Additionally, the FDA estimates it will approve up to 20 cell and gene therapy products a year by 2025. The development of cell and gene therapies has become an essential component of cancer and genetic disease research and treatment. As such, there has been a great deal of financing funneling toward cell and gene therapy research, with companies raising nearly $2.6 billion in the third quarter of 2019. Provided are articles that help pose and answer questions around the research element of cell and gene therapy.